Portfolio optimization impacts Ashland sales, boosts efficiency goals
Ashland’s portfolio optimization efforts, including exits from CMC, MC, nutraceuticals, and the Avoca business, reduced quarterly sales by 10%, while underlying sales declined by 5%.
U.S.A – Ashland Inc., a global supplier of additives and specialty ingredients, reported lower sales in its Specialty Additives segment during the third quarter of its fiscal year.
The segment, which includes food-related ingredients, brought in US$131 million, down 13% from US$150 million in the same period last year.
This decline was partly driven by Ashland’s deliberate move to streamline its business.
Previously announced optimization initiatives in the carboxymethylcellulose (CMC), methylcellulose (MC), nutraceuticals, and the Avoca botanical extracts portfolio, cut overall company sales by about $53 million, or 10% year-over-year.
Without these changes, the company’s total sales would have dropped just 5%.
Sales were still slow in regions like China, the Middle East, Africa, and India, reflecting softer demand and ongoing market challenges.
Despite this, Ashland maintained stable pricing, a small but essential gain considering the inflationary and competitive pressures across the industry.
Overall Company Performance
Ashland’s total third-quarter sales reached $463 million, down 15% compared to the same time last year.
This included a $53 million impact from product exits and restructuring. The company reported a net loss of $742 million, mainly due to a non-cash charge related to reduced market value. Still, adjusted earnings and cash flow stayed strong, backed by cost-cutting and operational streamlining.
Future Outlook
Despite current pressures, Ashland is focused on driving efficiency and restoring profit margins.
“Ashland delivered resilient performance in a mixed demand environment, with stable demand trends across most markets, though volumes fell short of expectations as anticipated growth did not materialize,” Chair and CEO Guillermo Novo acknowledged the headwinds but emphasized progress.
The company is consolidating parts of its production network, including facilities producing hydroxyethylcellulose (HEC), a key ingredient used in both food and personal care, to reduce costs and enhance output.
“These conditions underscore the importance of our sustained focus on cost savings and operational discipline, which continue to support strong margins,” Novo added.
Ashland has revised its full-year outlook slightly downward, now projecting fiscal 2025 sales between US$1.825 billion and US$1.850 billion, with adjusted EBITDA between $400 million and $410 million.
This outlook factors in Ashland’s ongoing portfolio optimization, including the strategic exit from certain lower-margin product lines such as carboxymethylcellulose (CMC), methylcellulose (MC), and specific nutraceuticals.
These compounds are commonly used in food and beverage formulations as stabilizers and texture enhancers. While this move reduced quarterly sales by about 10%, it reflects a deliberate pivot toward higher-margin, performance-driven ingredients.
Crucially, this does not indicate a complete exit from the food additives space. Instead, Ashland is repositioning its portfolio to focus on specialized functional ingredients, like hydroxyethylcellulose (HEC), that support texture, shelf life, and formulation stability, particularly in clean-label and value-added food products.
This shift is in line with evolving consumer preferences and the company’s broader goal to enhance profitability while staying relevant in its various businesses.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
